

02-12-01

A

10/60/20  
S. U. S.  
P. T. O.

# UTILITY PATENT APPLICATION TRANSMITTAL

## (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.  
RDID0028USTotal Pages in this Submission  
89TO THE ASSISTANT COMMISSIONER FOR PATENTSBox Patent Application  
Washington, D.C. 20231

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for my invention entitled:

**SYSTEM FOR SIMPLE NUCLEIC ACID ANALYSIS**

and invented by:

FRITZ, Michael; GERSTLE, Volker; HARTTIG, Herbert; SCHWAB, Juergen; STEINBISS, Joachim;  
and RAUSCHER, Andreas

If a CONTINUATION APPLICATION, check appropriate box and supply the requisite information:

 Continuation     Divisional     Continuation-in-part (CIP) of prior application No.: \_\_\_\_\_

Which is a:

 Continuation     Divisional     Continuation-in-part (CIP) of prior application No.: \_\_\_\_\_

Which is a:

 Continuation     Divisional     Continuation-in-part (CIP) of prior application No.: \_\_\_\_\_

Enclosed are:

**Application Elements**1.  Filing fee as calculated and transmitted as described below2.  Specification having 32 pages and including the following:

- a.  Descriptive Title of the Invention
- b.  Cross References to Related Applications (*if applicable*)
- c.  Statement Regarding Federally-sponsored Research/Development (*if applicable*)
- d.  Reference to Microfiche Appendix (*if applicable*)
- e.  Background of the Invention
- f.  Brief Summary of the Invention
- g.  Brief Description of the Drawings (*if drawings filed*)
- h.  Detailed Description
- i.  Claim(s) as Classified Below
- j.  Abstract of the Disclosure

# UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.  
RDID0028US

Total Pages in this Submission  
89

## Application Elements (Continued)

3.  Drawing(s) (when necessary as prescribed by 35 USC 113)

a.  Formal Number of Sheets \_\_\_\_\_  
b.  Informal Number of Sheets 7

4.  Oath or Declaration

a.  Newly executed (*original or copy*)  Unexecuted

b.  Copy from a prior application (37 CFR 1.63(d)) (*for continuation/divisional application only*)

c.  With Power of Attorney  Without Power of Attorney

d.  DELETION OF INVENTOR(S)

Signed statement attached deleting inventor(s) named in the prior application,  
see 37 C.F.R. 1.63(d)(2) and 1.33(b).

5.  Incorporation By Reference (*usable if Box 4b is checked*)

The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under  
Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby  
incorporated by reference therein.

6.  Computer Program in Microfiche (Appendix)

7.  Nucleotide and/or Amino Acid Sequence Submission (*if applicable, all must be included*)

a.  Paper Copy

b.  Computer Readable Copy (*identical to computer copy*)

c.  Statement Verifying Identical Paper and Computer Readable Copy

## Accompanying Application Parts

8.  Assignment Papers (*cover sheet & document(s)*)

9.  37 CFR 3.73(B) Statement (*when there is an assignee*)

10.  English Translation Document (*if applicable*)

11.  Information Disclosure Statement/PTO-1449  Copies of IDS Citations

12.  Preliminary Amendment (*to follow*)

13.  Acknowledgment postcard

14.  Certificate of Mailing

First Class  Express Mail (*Specify Label No.*): EL566557606US

P01ULRG/REV05

**UTILITY PATENT APPLICATION TRANSMITTAL  
(Large Entity)**

*(Only for new nonprovisional applications under 37 CFR 1.53(b))*

Docket No.  
RDID0028US

Total Pages in this Submission  
89

**Accompanying Application Parts (Continued)**

15.  Certified Copy of Priority Document(s) (if foreign priority is claimed)

16.  Additional Enclosures (please identify below):  
**General Appointment of Representative for U.S. Patent and Trademark Office Matters (1pp).**

**Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)**

17.  Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.

**Warning**

An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.

**UTILITY PATENT APPLICATION TRANSMITTAL**  
**(Large Entity)**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.  
**RDID0028US**

Total Pages in this Submission  
**89**

**Fee Calculation and Transmittal**


**CLAIMS AS FILED**

For	#Filed	#Allowed	#Extra	Rate	Fee
Total Claims		- 20 =	0	x \$18.00	\$0.00
Indep. Claims		- 3 =	0	x \$80.00	\$0.00
Multiple Dependent Claims (check if applicable)	<input type="checkbox"/>				
				BASIC FEE	\$0.00
				TOTAL FILING FEE	\$0.00

- A check in the amount of \_\_\_\_\_ to cover the filing fee is enclosed.
- The Commissioner is hereby authorized to charge and credit Deposit Account No. \_\_\_\_\_ as described below. A duplicate copy of this sheet is enclosed.
- Charge the amount of \_\_\_\_\_ as filing fee.
- Credit any overpayment.
- Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.
- Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).

Dated: **February 9, 2001**

CC:

  
*Brent A. Harris*  
Signature  
Brent A. Harris, Reg. No. 39,215  
Roche Diagnostics Corporation  
9115 Hague Road, Bldg. D  
P.O. Box 50457  
Indianapolis, IN 46250-0457  
Telephone No.: (317) 521-3104  
Facsimile No.: (317) 521-2883

**CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)**

Applicant(s): FRITZ, Michael, et al.

Docket No.

RDID0028US

Serial No.  
To Be Assigned

Filing Date  
February 9, 2001

Examiner  
To Be Assigned

Group Art Unit  
To Be Assigned

Invention: SYSTEM FOR SIMPLE NUCLEIC ACID ANALYSIS



I hereby certify that this

**U.S. Utility Patent Application**  
*(Identify type of correspondence)*

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under  
37 CFR 1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231 on  
February 9, 2001.

*(Date)*

Rose Edwards

*(Typed or Printed Name of Person Mailing Correspondence)*

*Rose Edwards*

*(Signature of Person Mailing Correspondence)*

EL566557606US

*("Express Mail" Mailing Label Number)*

Note: Each paper must have its own certificate of mailing.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Assistant Commissioner for Patents  
Washington, DC 20231




GENERAL APPOINTMENT OF REPRESENTATIVE FOR  
U.S. PATENT AND TRADEMARK OFFICE MATTERS

The undersigned applicant or assignee hereby appoints D. Michael Young, Reg. No. 33,819, Richard T. Knauer, Reg. No. 35,575, Brent A. Harris, Reg. No. 39,215, Kenneth J. Waite, Reg. No. 45,189, and Marilyn L. Amick, Reg. No. 30,444 all of Roche Diagnostics Corporation, 9115 Hague Road, P.O. Box 50457, Indianapolis, Indiana 46250, Telephone No. (317) 845-2000, and Jill Lynn Woodburn, Reg. No. 39,874 of The Law Office of Jill L. Woodburn, L.L.C., 6633 Old Stonehouse Drive, Newburgh, Indiana 47630-1785, Telephone No. (812) 842-2660:

to prosecute and transact all business on its behalf before the United States Patent and Trademark Office in connection with any U.S. patent assigned to it and any U.S. patent application filed by it or on its behalf and to receive payments on its behalf.

Signed this 18<sup>th</sup> day of September, 2000 at Mannheim, Germany.

Roche Diagnostics GmbH

  
Signature


Dr. Michael Jung

Print Name

Director

Position or Title

Roche Diagnostics GmbH

  
Signature

Dr. Manfred Weber

Print Name

Senior Director

Position or Title